November 27, 2015
Recommended Topic Related To:


"SILVER SPRING, MD ” The US Food and Drug Administration (FDA) is updating labeling information for the hepatitis C antivirals ledipasvir/sofosbuvir (Harvoni, Gilead Sciences) and sofosbuvir (Sovaldi, Gilead Sciences) after th"...




Human experience of overdose with OLYSIO is limited. There is no specific antidote for overdose with OLYSIO. In the event of an overdose, the patient's clinical status should be observed and the usual supportive measures employed.

Simeprevir is highly protein-bound; therefore, dialysis is unlikely to result in significant removal of simeprevir [see CLINICAL PHARMACOLOGY].


There are no specific contraindications to OLYSIO.

The contraindications to other antiviral drugs administered with OLYSIO for the treatment of CHC infection also apply to OLYSIO combination treatment. Prescribers should consult the complete prescribing information for these drugs for a description of contraindications.

If OLYSIO is administered with Peg-IFN-alfa and RBV, the contraindications for use of Peg-IFN-alfa and RBV also apply to this combination regimen. Refer to the prescribing information for Peg-IFN-alfa and RBV for a list of all contraindications.

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 11/12/2015


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.